About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group is dedicated to paediatric research. We are interested in rare respiratory and endocrinological diseases, and also in common paediatric problems such as normal growth, asthma, neonatal pathology and imaging diagnosis, as well as minority diseases. Our goal is to transfer the findings of clinical and genetic studies to the widespread clinical practice and the general population, with the long-term objective of obtaining better diagnoses, implementing better therapeutic practices and improving the health of children.
Our group is part of CIBERER (Biomedical Research Networking Centre on Rare Diseases) (CIBERER U712) and European Reference Networks (ERN) for rare diseases ERN LUNG and Endo-ERN.
We have created and are implementing and evaluating the outcomes of an educational program to treat paediatric obesity (Niñ@s en Movimiento®).
IP: Diego Yeste Fernandez
4.1 Disorders of sex development (DSD): clinical and molecular diagnosis. We analyse known genes involved in human sexual differentiation and search for new genes.
4.2 Program of molecular diagnosis of thyroid dyshormonogenesis in patients with hypothyroidism which have been diagnosed at the newborn screening program. The objective of this project is to advance in the identification and characterization of the molecular basis of the patients with thyroid dyshormonogenesis through the implementation of next generation sequencing techniques (NGS) to later translate these results to the routine diagnosis of the detected patients in the program of Neonatal Screening of Congenital Hypothyroidism. Our group is reference centre for Catalonia. 4.3 Familial isolated glucocorticoid deficiency: clinical and molecular diagnosis. We analyse known genes involved in familial isolated glucocorticoid deficiency and search for new genes.
4.4 Congenital hyperinsulinism: clinical and molecular diagnosis. We analyse known genes involved in congenital hyperinsulinism and search for new genes.
IP: Diego Yeste Fernandez, Maria Clemente Leon, Monica Fernandez Cancio
Longitudinal study of growth 1995-2017. Longitudinal studies of growth require a very long follow-up period, about 20 years, but they allow to correctly evaluate pubertal growth by providing differentiated data for children who initiate pubertal maturation at an early, intermediate or late time. In this study, 1,453 healthy non-obese subjects (743 women, 710 males) who reached adult height between January 2012 and January 2017 were included, which allowed the development of height, weight and body mass index charts, with the particularity of including separated charts for the different phenotypes of pubertal maturation (very early, early, intermediate, late and very late). This allows a much more accurate assessment of pubertal growth.
In addition to the publication of the results, a website "Millennials Growth. Longitudinal growth study 1995-2017", which includes the growth charts performed with the LMS method, an auxologic calculation program for health professionals, and two Apps (Android and iOS) has been developed. This will allow their use by all health professionals and we believe it will be a very valuable tool for the assessment and monitoring of normal and pathological growth in children.
IP: Monica Fernandez Cancio
We are exploring the role of new imaging techniques in children with congenital malformations and other rare diseases with the aim of improving their diagnosis and avoid radiation exposure.
IP: Josefa Élida Vázquez Méndez
IP: Maria Clemente Leon Collaborators: María Antolín Mate, Diego Yeste Fernandez, Nuria Gonzalez Llorens, Ariadna Campos Martorell, Cristina Aguilar Riera, Eduard Mogas Viñas Funding agency: Instituto de Salud Carlos III Funding: 106250 Reference: PI24/01376 Duration: 01/01/2025 - 31/12/2027
IP: Nerea Maiz Elizaran Collaborators: Josefa Élida Vázquez Méndez, Marta Codina Solà, Ma Irene Valenzuela Palafoll, Silvia Arévalo Martínez, Carlota Rodó Rodríguez, Eulàlia Rovira Moreno, David Gómez Andrés, Amaia Lasa Aranzasti, Elena Moreno Perez Funding agency: Fundació La Marató de TV3 Funding: 197000 Reference: 202420-10 Duration: 20/02/2025 - 19/02/2028
IP: Anna Gros Turpin Collaborators: Laura Gonzalez Garcia, Patricia Rubio Garrido, Raquel Rodríguez Gil, Javier Garcia Fernandez, Pablo Buck Sainz Funding agency: Col·legi Oficial d'Infermers/es de Barcelona Funding: 5830 Reference: PR-730/2024 Duration: 01/01/2025 - 31/12/2026
IP: Inmaculada Fuentes Camps Collaborators: Antonio Moreno Galdó, Rafael Simó Canonge, Ariadna Martín Balcells, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Joan Genescà Ferrer, Gemma Vona Giralt, Paula Isabel Roldan Caballero Funding agency: Instituto de Salud Carlos III Funding: 274920 Reference: PT23/00062 Duration: 01/01/2024 - 31/12/2026
PhD student: Noelia Baz Redón Director/s: Nuria Camats Tarruella, Antonio Moreno Galdó University: Universitat Autònoma de Barcelona Year: 2022
PhD student: Alba Torrent Vernetta Director/s: Antonio Moreno Galdó University: Universidad Autònoma de Barcelona Year: 2021
PhD student: Laura Soler Colomer Director/s: Diego Yeste Fernandez University: Universidad Autònoma de Barcelona Year: 2020
PhD student: Sandra Rovira Amigo Director/s: Antonio Moreno Galdó University: Universidad Autònoma de Barcelona Year: 2020
PhD student: Angela Gregoraci Fernández Director/s: Félix Castillo Salinas University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Ferran Rosés i Noguer Director/s: Antonio Moreno Galdó University: Universidad Autònoma de Barcelona Year: 2018
PhD student: Josefa Élida Vázquez Méndez Director/s: Antonio Carrascosa Lezcano, Antonio Carrascosa Lezcano University: Universidad Autònoma de Barcelona Year: 2018
PhD student: Director/s: Maria Clemente Leon University: Universitat Autònoma de Barcelona Year: 2017
PhD student: Nuria Camats Tarruella Director/s: University: Universidad Autònoma de Barcelona Year: 2009
PhD student: Monica Fernandez Cancio, Monica Fernandez Cancio Director/s: University: Universitat de Barcelona Year: 2006
PhD student: Miguel Gussinyé Cañadel Director/s: University: Universidad Autònoma de Barcelona Year: 2005
PhD student: Maria Clemente Leon, Maria Clemente Leon Director/s: University: Universidad Autònoma de Barcelona Year: 2003
The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.
Es va reconèixer la tasca de més de 70 professionals dedicades a aquesta malaltia pulmonar, tant assistencial com de recerca.
The two studies awarded has been the research for a the ciliary dyskinesia diagnosis led by the VHIR’s Growth and Development Group and the EPISCAN II, in which Dr. Miravitlles has participated.
